menu

TROP2-Directed ADCs in Lung Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Deep Dive into the Management of AEs Associated with ADCs

TROP2-Directed ADCs in Lung Cancer

Minute CME/CE
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
of 1.00 program credits
Claim credits How to claim
Credits Claimed -
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    In recent years, several antibody-drug conjugates (ADCs) were approved across a variety of solid tumors. This presents challenges when managing a multitude of treatment-related adverse events, some of which may lead clinicians into unfamiliar territory. This series of educational activities focuses on appropriate management of ADC-related adverse events in breast, lung, gastric, and bladder cancers.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Jaffer A. Ajani, MD
    Professor, Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Research: Daiichi Sankyo
    Consulting Fees: AstraZeneca, Daiichi Sankyo

    Justin Gainor, MD
    Director, Center for Thoracic Cancers
    Director, Targeted Immunotherapy
    Massachusetts General Hospital
    Boston, MA

    Contracted Research: Adaptimmune, Alexo, Ariad/Takeda, Array, BMS, Blueprint, Genentech/ Roche, Jounce, Merck, Moderna, Novartis, Scholar Rock, and Tesaro
    Consulting Fees: Agios, Amgen, Ariad/Takeda, Array, AstraZeneca, BMS, Clovis Oncology, EMD Serono, Genentech, Glyde Bio, Helsinn, Incyte, Jounce, Karyopharm, Loxo, Merck, Mirati, Novartis, Oncorus, Pfizer, and Regeneron

    Sara Hurvitz, MD
    Professor of Medicine
    David Geffen School of Medicine, UCLA
    Santa Monica, CA

    Contracted Research: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX, Daiichi Sankyo, Dignitana, Eli Lilly, Genentech/Roche, Gilead, GSK, Immunomedics, MacroGenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Sanofi, Seattle Genetics/Seagen, Zymeworks
    Preclinical Work: Ambrx, Samumed
    National/International PI: Daiichi Sankyo, GNE/Roche, Novartis, SeaGen
    Steering Committee: Daiichi-Sankyo/AZ, GNE/Roche, Lilly, Novartis, Sanofi
    Uncompensated consulting/ad boards: 4DPharma, Ambrx, Amgen, Artios, Arvinas, Biotheranostics, Daiichi Sankyo, Dantari, Eli Lilly, Genentech/Roche, Immunomedics, MacroGenics, NKMax, Novartis, Pieris, Pyxis, Seagen
    Travel: Lilly

    Gopa Iyer, MD
    Associate Attending Physician
    Section Head, Urothelial Carcinoma
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Research: Aadi Biosciences, Janssen, Mirati Therapeutics, SeaGen
    Consulting Fees: Basilea, EMD Serono, Flare Therapeutics, Gilead, Loxo Oncology, Silverback Therapeutics, The Lynx Group

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo, PSM has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed., RN, OCN has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the components of an antibody-drug conjugate (ADC) that may cause adverse events (AEs)
    • Recognize AEs that lead to treatment interruption or discontinuation
    • Recommend an approach for managing the key AEs associated with ADCs
    • Design a mitigation plan for AEs in patients at high risk for ADC-related AEs 
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pulmonologists, urologists, pathologists, oncology nurse practitioners, physician assistants, oncology nurses, oncology pharmacists, and other HCPs managing patients with solid tumors.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 hour of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 06/30/2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for 1.0 contact hours 0.1 CEUs by Global Learning Collaborative (GLC).  GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is UAN JA0006235-0000-22-029-H01-P. This learning activity is enduring-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Customize your experience based on your profession
Profession
Registration is a short process and your information will be kept safe.
How To Claim Credit
Minute CME/CE is a short-form content that puts you in control of the education you consume.
Profession

Engage in Content

Click Claim Button

Track Your Status

Upon completion of Program Evaluation, your certificate will automatically appear. You may check the status of all credits claimed and certificates received by visiting your Profile.
Schedule8 Aug 2022
Webpack App